Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

BACKGROUND: There are two FDA‐approved anti‐CD38 monoclonal antibodies for treatment of multiple myeloma: isatuximab and daratumumab. Owing to expression of CD38 on reagent red blood cells (RBCs), these antibodies interfere with indirect antiglobulin tests (IATs). We sought to understand differences...

Descripción completa

Detalles Bibliográficos
Autores principales: Chami, Btissam, Okuda, Makoto, Moayeri, Morvarid, Pirenne, France, Hidaka, Yoko, Nambiar, Ashok, Song, Zhili, Bedel, Olivier, Zhang, Bailin, Hopke, Joern, Deng, Gejing, Zhu, Chen, Macé, Sandrine, Chiron, Marielle, Adrian, Francisco, Fukao, Taro, Basile, Frank G., Martin, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Immunohematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828815/
https://www.ncbi.nlm.nih.gov/pubmed/36239134
http://dx.doi.org/10.1111/trf.17137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828815/
https://www.ncbi.nlm.nih.gov/pubmed/36239134
http://dx.doi.org/10.1111/trf.17137

Ejemplares similares